Mexico rejects Nestle's buyout of Pfizer nutrition unit; Apotex sues Daiichi over Benicar patent;

@FiercePharma: Novartis nabs FDA approval for 1st flu vaccine made without eggs. Produced at plant that got $500M in gov't aid. More (sub. req.) | Follow @FiercePharma

> Mexican regulators blocked Nestle's acquisition of Pfizer's ($PFE) nutrition unit in that country, saying the deal would give Swiss-based Nestle up to 88% of the baby formula market, clearing the way for price increases. Report

> Apotex petitioned a U.S. court to rule that its plan to sell a generic version of Daiichi Sankyo's Benicar blood pressure drug wouldn't step on the Japanese company's patents. Report

> The American College of Obstetricians and Gynecologists recommended that birth control pills be made available over the counter. Report

> Administering the sleep drug Ambien or its combination-pill sister Intermezzo to hospital patients may help them rest but may also substantially increase their risk of a fall, a study found. Report

> The WHO said that drug marketing practices may amp up antibiotic use in a way that facilitates the spread of superbugs. Report

> Xoma's ($XOMA) combination of two generic hypertension drugs lowered blood pressure than either of the drugs alone, a study found. Report

Medical Device News

 @FierceMedDev: FDA faults St. Jude's manufacturing for Durata ICD leads. St. Jude disclosed the report but kept "Durata" out. More | Follow @FierceMedDev

 @MarkHFierce: Zimmer will train regulators in China in an unusual deal. Release | Follow @MarkHFierce

 @DamianFierce: Novartis' Alcon is buying the ophthalmic surgery unit of German company SensoMotoric. Story | Follow @DamianFierce

> Boston Scientific gets CE mark for expanded CRM longevity. Article

> HeartWare snags FDA approval for novel heart pump. News

Biotech News

 @FierceBiotech: Predicting your end: Biomarkers for mortality. News | Follow @FierceBiotech

 @JohnCFierce: Feds zero in on drug experts as insider case exposes investigator's role (more to come, I suspect). Story | Follow @JohnCFierce

 @RyanMFierce: With ex-BMSer Jeremy Levin at the helm, Teva wants to do buyouts that are smaller than the deals that made Teva big. More | Follow @RyanMFierce

> Xoma hunts for marketing partner as blood pressure med clears PhIII. Article

> Pfizer, Bristol-Myers win landmark European approval for Eliquis. Story

Drug Delivery News

> Fujifilm joins microneedle R&D boom. Report

> Reinforced gels deliver drugs and cells. Article

> Pfizer hits ups, downs with controlled-release Lyrica. News

> Nanoparticles deliver antigen to trick the immune system in MS. Story

Biomarkers News

> Predicting your end: Biomarkers for mortality. Article

> Kidney problems tag development delays? Story

> Saliva markers diagnose gum disease. News

> DoD's $1.15M grant may lead to blood test to catch heavy drinkers. Item

Vaccine News

> J&J hits development roadblock with Crucell candidates. Article

> FDA panel concerned about safety of Dynavax's hep B vaccine. News

> Novartis nabs EU committee backing for meningitis B vaccine. Story

> GSK's Synflorix gleans positive results in infants. Report

> FDA approves Novartis flu vaccine. Item

And Finally... U.S. officials tracking down the purveyors of fake Avastin may find common cause with Mark Twain, who lambasted a bogus medicine salesman in a scathing 1905 letter. Report | Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.